LSL Web-Exclusive Content

  1. 4 Emerging Commercialization Strategies For Gene And Cell Therapies
    11/1/2018

    Progress in development of gene and cell therapies around the world has potential to transform standards of care for a range of diseases and address significant areas of unmet need in healthcare over the coming years. In the U.S. alone, almost 20 gene and cell therapy products have been approved thus far,1 with many other development programs reaching later clinical stages. The technology platforms of many of these drugs also offer the potential for curative efficacy and expansion for use in multiple indications.

  2. How Amgen Uses AI Tools To Improve Manufacturing Deviation Investigations
    10/26/2018

    Amgen is piloting a process using artificial intelligence (AI) that has the potential to greatly enhance its ability to trend and find patterns in manufacturing deviations and to prevent their recurrence. The AI tool will look across large data sets and find correlations between obscure signals and events which the previous system could have missed.

  3. Be Brave, Be Curious, Be Determined.
    10/25/2018

    Some leadership steps to take when you want to engage employees, colleagues, partners and customers to join you in your quest for knowledge to find cures to today’s most pressing business challenges.

  4. The Top 5 Trends To Watch In Bioprocessing
    10/24/2018

    Biopharmaceutical processes — and the technologies that enable them — have experienced remarkable progress in the past 30 years, since the first biopharmaceuticals were approved for human use. This article will highlight some of today’s top trends in bioprocessing, as this exciting field continues to flourish.

  5. 7 Reasons There Was Never Going To Be A Bioprocessing Capacity Crunch
    10/22/2018

    “Basically, industry perceives, reports, and expects no major capacity crunches” related to global bioprocessing needs. So concludes an editor of BioPlan Associates, Inc.’s Fifteenth Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production (April 2018), in a response to my recent editorial saying as much. Now we have the data to back the assertions up.  

  6. Improving Training In Biopharmaceutical Manufacturing
    10/19/2018

    The bioprocessing industry is continuing to invest in training as it seeks to avoid problems and capacity constraints. And while budgets are increasing, new practices such as online components, standardization, and the development of accredited/certified training have not been adopted yet. 

  7. Biosimilar Policies To Watch As We Approach 2019
    10/18/2018

    I reached out to Biosimilar Development editorial board member Molly Burich of Boehringer Ingelheim for her input on the policies she expects could have the largest positive or negative impact on biosimilars, as well as what progress has been made on the policy front.

  8. The Current State Of U.S. Biosimilar Policies — An Overview
    10/17/2018

    With the continued policy dialogue on how rising drug costs impact patient access, the theoretical cost savings that biosimilars may offer is intriguing to many policymakers as well as those in the industry. 

  9. A Possible “Humirageddon:” Perspectives On The EU Biosimilar Launch
    10/16/2018

    In the wake of the arrival of Humira biosimilars in the EU, Jorge Santos da Silva and Jennifer Heller of McKinsey & Company share several critical pricing and market considerations for companies as this highly anticipated product finally becomes available to patients.

  10. The State Of IT Security In The Pharma Industry Today
    10/12/2018

    The current state of cybersecurity -- especially pharmaceutical, biotechnology, or other high sensitive environments such as those in the financial sectors -- has never been more pressing than it is right now.